CRANBURY, N.J., Feb. 8, 2017 /PRNewswire/ -- Cornerstone
Pharmaceuticals, Inc. today announced a number of additions to its
Scientific and Medical Advisory Boards, continuing the company's
recent momentum of growth in its management team and governing and
advisory bodies. Members of Cornerstone's Scientific and Medical
Advisory Boards are highly regarded researchers and physicians
within the fields of oncology, hematology and lymphoma. They will
help strengthen Cornerstone's drug development and
commercialization capabilities at a pivotal time in the company's
lifecycle, and provide guidance on the company's clinical trial
strategy.
"Innovation in oncology drug development requires a
multidisciplinary team comprised of experts in the scientific and
medical fields. We have assembled unparalleled boards of
scientific and medical advisors who will work with Cornerstone to
help revolutionize anticancer treatment among our prime treatment
targets: pancreatic cancer, acute myeloid leukemia and lymphoma,"
said Howard Jonas, Chairman of the
Board of Cornerstone. "The combination of skills among the
world-renowned cell biologists, oncology researchers and clinical
oncologists on the advisory boards will further enhance
Cornerstone's ability to develop and advance our cutting-edge
R&D pipeline."
Chi Van Dang, M.D., Ph.D., the
incoming Chair of the Scientific and Medical Advisory Boards said,
"The addition of such highly regarded and experienced scientific
and medical advisors, better positions Cornerstone as an incoming
leader in the growing field of metabolic cancer therapy. I am
excited to have the opportunity to work alongside such uniquely
qualified colleagues."
Chair of the Scientific and Medical Advisory Boards
Chi Van Dang, M.D., Ph.D.:
Director of the Abramson Cancer Center of the University of Pennsylvania until July 1, 2017, when he will become Scientific
Director of the Ludwig Institute for Cancer Research. Dr. Dang is
considered by many to be the world's leading authority on cancer
metabolism. Dr. Dang is also serving on Cornerstone's Board of
Directors.
Scientific Advisory Board
- Dafna Bar-Sagi, Ph.D.:
Senior Vice President, Vice Dean for Science, Chief Scientific
Officer, Professor, Departments of Biochemistry and Molecular
Pharmacology, and Medicine, NYU Langone Medical Center
- Navdeep S. Chandel,
Ph.D.: David W. Cugell Professor of Medicine and Cell
Biology at Northwestern University
Feinberg School of Medicine; Author of "Navigating Metabolism"
(Cold Spring Harbor Press)
- Alec Kimmelman, M.D.,
Ph.D.: Professor, Department of Radiation Oncology,
Chair, Department of Radiation Oncology, NYU Langone Medical
Center
- Gregg Semenza, M.D.,
Ph.D.: Director, Vascular Program, Institute for Cell
Engineering; Professor of Pediatrics, Radiation Oncology and
Molecular Radiation Sciences, Biological Chemistry, Medicine, and
Oncology at the Johns Hopkins University
School of Medicine. 2016 Lasker Award
recipient
Medical Advisory Board
Pancreatic Cancer Advisors
- Jordan D. Berlin, M.D.:
Co-leader, Gastrointestinal Cancer Research Program, Professor
of Medicine (Hematology/Oncology), Director, Phase I Program,
Medical Oncologist, Vanderbilt-Ingram Cancer Center
- J. Randolph Hecht,
M.D.: Director, Gastrointestinal Cancer Program,
Professor of Clinical Medicine, David
Geffen School of Medicine at UCLA
- William Isacoff, M.D.:
Department of Medicine, David Geffen-UCLA School of Medicine;
Board of Directors of the Jonsson Comprehensive Cancer
Foundation
- Philip A. Philip, M.D.,
Ph.D., F.R.C.P.: Professor of Oncology and Pharmacology,
Leader, GI and Neuroendocrine Oncology, Vice President of Medical
Affairs, Karmanos Cancer Center, Wayne State
University
- Heloisa P. Soares, M.D.,
Ph.D.: Medical Oncologist, Department of Gastrointestinal
Oncology, Moffitt Cancer Center
Acute Myeloid Leukemia Advisors
- Jorge Cortes, M.D.:
Deputy Chair and Professor of Medicine in the Department of
Leukemia at The University of Texas MD
Anderson Cancer Center
- Bayard L. Powell, M.D.:
Section Chief, Hematology & Oncology, Associate Director for
Clinical Research, Comprehensive Cancer Center, Professor,
Hematology & Oncology, Wake Forest Baptist Medical
Center
- Mikkael Sekeres,
M.D.: Director, Leukemia Program, Vice-chair for Clinical
Research, Cleveland Clinic's Taussig
Cancer Institute
- Richard M. Stone, M.D.:
Professor of Medicine, Harvard Medical
School; Associate Physician, Medicine, Brigham And Women's
Hospital; Director, Adult Leukemia Program, Dana-Farber Cancer
Institute
Lymphoma Advisors
- Craig H. Moskowitz, M.D.:
Hematologist, Clinical Director of the Division of Hematologic
Oncology, Memorial Sloan Kettering Cancer Center
- Steven I. Park, M.D.:
Director, Lymphoma Program, Associate Professor of Medicine, UNC
Lineberger Comprehensive Cancer Center
About Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. is a clinical-stage,
oncology-focused pharmaceutical company committed to the
development and commercialization of therapies that exploit the
metabolic differences between normal cells and cancer cells.
Cornerstone's primary objective is to develop highly selective and
effective agents with minimal toxic effects on normal cells and
tissues. Cornerstone's first-in-class clinical lead compound,
CPI-613 is being evaluated in multiple Phase I, I/II, and II
clinical studies. The U.S. Food and Drug Administration (FDA) has
designated CPI-613 an orphan drug for the treatment of acute
myeloid leukemia (AML), pancreatic cancer and myelodysplastic
syndromes (MDS). The company's investors include IDT Corporation
(NYSE: IDT). For more information, visit:
www.cornerstonepharma.com.
Safe Harbor Statement
This press release contains forward-looking statements. These
statements relate to future events or the company's future
financial performance. In some cases, you can identify
forward-looking statements by terminology such as "may", "will",
"should", "expect", "plan", "anticipate", "believe", "estimate",
"predict", "potential" or "continue", the negative of such terms,
or other comparable terminology. These statements are only
predictions. Actual events or results may differ materially from
those in the forward-looking statements as a result of various
important factors. Although we believe that the expectations
reflected in the forward-looking statements are reasonable, such
statements should not be regarded as a representation by the
company, or any other person, that such forward looking statements
will be achieved. The business and operations of the company are
subject to substantial risks which increase the uncertainty
inherent in forward-looking statements. We undertake no duty to
update any of the forward-looking statements, whether as a result
of new information, future events or otherwise. In light of the
foregoing, readers are cautioned not to place undue reliance on
such forward-looking statements.
Contact:
|
Jacob
Jonas
|
|
Public Relations,
Cornerstone Pharmaceuticals, Inc.
|
|
jacob@cornerstonepharma.com
|
|
|
|
Kara Golub
|
|
JFK Communications,
Inc.
|
|
609-456-0822
|
|
kgolub@jfkhealth.com
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cornerstone-pharmaceuticals-inc-announces-the-addition-of-world-renowned-experts-to-scientific-and-medical-advisory-boards-300404070.html
SOURCE Cornerstone Pharmaceuticals, Inc.